MarketPulse
A

$ATRA

26 articles found
0 positive
25 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Law Offices Of Howard G. Smith

Four Public Companies Face Securities Fraud Claims as Investor Deadline Looms

Four public companies face securities fraud class actions alleging false statements. Investor deadline for lead plaintiff motions set for late May 2026.
IBRXSMCICOTYATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Atara Biotherapeutics Faces Class Action Over FDA Approval Claims

Class action lawsuit filed against Atara Biotherapeutics alleges false statements about FDA approval prospects. Investors must seek lead plaintiff status by May 22, 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Hit With Securities Lawsuit Over Manufacturing, Study Claims

Rosen Law Firm urges $ATRA investors to meet May 22, 2026 deadline in securities lawsuit alleging false statements about manufacturing and clinical trial deficiencies.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Candidate

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
AQSTSLNOATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Atara Biotherapeutics Hit With Securities Fraud Class Action Over Failed Drug Approval

Pomerantz Law Firm files class action against $ATRA over alleged misstatements regarding tabelecleucel's regulatory prospects, following FDA rejections and severe stock declines.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Atara Biotherapeutics Faces Securities Fraud Suit Over Concealed FDA Obstacles

Class action lawsuit alleges $ATRA misrepresented manufacturing issues and clinical trial deficiencies for tabelecleucel, obscuring FDA approval challenges between May 2024 and January 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Hit With Class Action Over Misleading Manufacturing Claims

Bronstein, Gewirtz & Grossman files class action against $ATAR, alleging executives misled investors about manufacturing issues and FDA approval prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ATRA Stock Investors Face Critical Deadline in Securities Class Action Over FDA Setback

Securities lawsuit filed against Atara Biotherapeutics over alleged misstatements regarding tabelecleucel manufacturing and failed ALLELE study. Lead plaintiff deadline May 22, 2026.
ATRAinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Securities Fraud Lawsuit Over Concealed Manufacturing, Clinical Trial Issues

Schall Law Firm launches securities fraud lawsuit against Atara Biotherapeutics for allegedly misrepresenting manufacturing capabilities and tabelecleucel trial results during May 2024-January 2026 period.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ATRA Faces Securities Fraud Lawsuit Over Misleading FDA Prospects and Manufacturing Claims

Class action lawsuit filed against Atara Biotherapeutics alleging false statements about manufacturing issues and regulatory prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

ATRA Stock Crashes 97% Total as FDA Rejects Cancer Drug Twice; Class Action Lawsuit Looms

Atara Biotherapeutics stock collapsed 97% across two FDA rejections for tabelecleucel. Class action deadline: May 22, 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Approval

Class action lawsuit filed against $ATARA alleging executives misled investors about manufacturing issues and study deficiencies affecting tabelecleucel FDA approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ATRA Faces Securities Lawsuit Over Tabelecleucel Setbacks; Lead Plaintiff Deadline Looms

Atara Biotherapeutics faces class action lawsuit alleging false statements about manufacturing and ALLELE study deficiencies. Lead plaintiff deadline set for May 22, 2026.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Securities Fraud Lawsuit Over Misleading Drug Trial Claims

Schall Law Firm launches class action against $ATRA for allegedly concealing manufacturing problems and overstating tabelecleucel prospects in ALLELE study.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

ATRA Faces Securities Class Action Over FDA Drug Approval Setbacks

Shareholders sue Atara Biotherapeutics for allegedly misleading statements on manufacturing issues and failed ALLELE study data affecting tabelecleucel approval prospects.
ATRAshareholder lawsuitsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Atara Biotherapeutics Faces Class Action Over Alleged Securities Fraud

Schall Law Firm recruits investors for class action against Atara Biotherapeutics over alleged securities fraud involving tabelecleucel drug and ALLELE study claims, covering May 2024-January 2026 purchases.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Lawsuit Targets Atara Biotherapeutics Over Tabelecleucel Disclosure Failures

Securities lawsuit alleges Atara Biotherapeutics concealed manufacturing issues and clinical study deficiencies for tabelecleucel. Investors with $100K+ losses must act before May 22, 2026 deadline.
ATRAinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Class Action Over FDA Study Misstatements

Securities lawsuit filed against $ATRA over alleged false statements on manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Atara Biotherapeutics Faces Securities Fraud Class Action Over Failed Drug Candidate

Class action lawsuit filed against $ATRA over alleged misstatements on tabelecleucel prospects. FDA rejected drug twice; stock crashed 40-57% post-announcements.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ATRA Hit With Securities Fraud Suit Over Manufacturing Issues, Regulatory Misstatements

Atara Biotherapeutics faces securities fraud class action for allegedly misrepresenting manufacturing capabilities and overstating regulatory prospects for tabelecleucel between May 2024 and January 2026.
CWHINOATRAsecurities fraudclass action lawsuit